NCT00517361View on ClinicalTrials.gov

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2012

Conditions

Metastatic Breast Cancer

Interventions

DRUG

carboplatin

AUC 6 in 250mL saline IV over 30 minutes

DRUG

bevacizumab

15mg/kg in 100mL saline IV over 60 - 90 minutes

Trial Locations (2)

60068

Oncology Specialists, Park Ridge

60637

University of Chicago, Chicago

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Chicago

OTHER